MTOR and non-small cell lung carcinoma: Our present study showed no much genomic alteration changes following chemotherapy treatment in PI3K/MTOR pathway, indicating that the combination of MTOR inhibitor and chemotherapy may be an effective therapeutic strategy for NSCLC.